Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant

Methods in Molecular Biology

Volumn 1403, Issue , 2016, Pages 269-284

  McPherson, Clifton ^a   Chubet, Richard ^a   Holtz, Kathy ^a   Honda Okubo, Yoshikazu ^a   Barnard, Dale ^a   Cox, Manon ^a   Petrovsky, Nikolai ^a  

^a NONE

Author keywords

Adjuvant; Advax adjuvant; Baculovirus; CGMP; Coronavirus; Delta inulin; Manufacture; MERS; SARS; Vaccine

Indexed keywords

DELTA INULIN; IMMUNOLOGICAL ADJUVANT; INULIN; RECOMBINANT PROTEIN; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS SPIKE PROTEIN; CORONAVIRUS SPIKE GLYCOPROTEIN; VIRUS VACCINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; FEMALE; GENE EXPRESSION SYSTEM; IMMUNOGENICITY; INSECT CELL; MOUSE; NONHUMAN; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VACCINE PRODUCTION; VIRUS EXPRESSION; VIRUS PURIFICATION; ANIMAL; HUMAN; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; INULIN; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; SPIKE GLYCOPROTEIN, CORONAVIRUS; VIRAL VACCINES;

EID: 84963799453     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4939-3387-7_14     Document Type: Chapter

References (33)

1. Nicholls J, Dong XP, Jiang G et al (2003) SARS: clinical virology and pathogenesis. Respirology 8 Suppl:S6–S8
2. Berger A, Drosten C, Doerr HW et al (2004) Severe acute respiratory syndrome (SARS)— paradigm of an emerging viral infection. J Clin Virol 29:13–22
3. Assiri A, McGeer A, Perl TM et al (2013) Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369:407–416
4. Marra MA, Jones SJ, Astell CR et al (2003) The Genome sequence of the SARS-associated coronavirus. Science 300:1399–1404
5. Darnell ME, Plant EP, Watanabe H et al (2007) Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J Infect Dis 196:1329–1338
6. Bolles M, Deming D, Long K et al (2011) A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinfl ammatory pulmonary response upon challenge. J Virol 85: 12201–12215
7. See RH, Zakhartchouk AN, Petric M et al (2006) Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus. J Gen Virol 87:641–650
8. Yasui F, Kai C, Kitabatake M et al (2008) Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARSCoV. J Immunol 181:6337–6348
9. Tseng CT, Sbrana E, Iwata-Yoshikawa N et al (2012) Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 7, e35421
10. Clay C, Donart N, Fomukong N et al (2012) Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung infl ammation upon homologous rechallenge. J Virol 86:4234–4244
11. Roper RL, Rehm KE (2009) SARS vaccines: where are we? Expert Rev Vaccines 8:887–898
12. Li W, Moore MJ, Vasilieva N et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426:450–454
13. Jeffers SA, Tusell SM, Gillim-Ross L et al (2004) CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 101:15748–15753
14. He Y, Zhou Y, Wu H et al (2004) Identifi cation of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines. J Immunol 173: 4050–4057
15. He Y, Lu H, Siddiqui P et al (2005) Receptorbinding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 174:4908–4915
16. Huang J, Cao Y, Du J et al (2007) Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specifi c for CD4+ and CD8+ T cells promote cellular immune responses. Vaccine 25:6981–6991
17. Zhou Z, Post P, Chubet R et al (2006) A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARSassociated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine 24: 3624–3631
18. Openshaw PJ, Culley FJ, Olszewska W (2001) Immunopathogenesis of vaccine-enhanced RSV disease. Vaccine 20 Suppl 1:S27–S31
19. Petrovsky N, Aguilar JC (2004) Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82:488–496
20. Cooper PD, Barclay TG, Ginic-Markovic M et al (2013) The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions. Glycobiology 23:1164–1174
21. Cooper PD, Petrovsky N (2011) Delta inulin: a novel, immunologically active, stable packing structure comprising beta-D-[2 -> 1] poly(fructo-furanosyl) alpha-D-glucose polymers. Glycobiology 21:595–606
22. Honda-Okubo Y, Saade F, Petrovsky N (2012) Advax, a polysaccharide adjuvant derived from delta inulin, provides improved infl uenza vaccine protection through broad-based enhancement of adaptive immune responses. Vaccine 30:5373–5381
23. Lobigs M, Pavy M, Hall RA et al (2010) An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous fl aviviruses. J Gen Virol 91: 1407–1417
24. Feinen B, Petrovsky N, Verma A et al (2014) Advax-adjuvanted recombinant protective antigen provides protection against inhalational anthrax that is further enhanced by addition of murabutide adjuvant. Clin Vaccine Immunol 21:580–586
25. Honda-Okubo Y, Kolpe A, Li L et al (2014) A single immunization with inactivated H1N1 infl uenza vaccine formulated with delta inulin adjuvant (Advax) overcomes pregnancyassociated immune suppression and enhances passive neonatal protection. Vaccine 32:4651–4659
26. Larena M, Prow NA, Hall RA et al (2013) JE-ADVAX vaccine protection against Japanese encephalitis virus mediated by memory B cells in the absence of CD8+ T cells and preexposure neutralizing antibody. J Virol 87:4395–4402
27. Layton RC, Petrovsky N, Gigliotti AP et al (2011) Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. Vaccine 29:6242–6251
28. Petrovsky N, Larena M, Siddharthan V et al (2013) An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody. J Virol 87:10324–10333
29. Saade F, Honda-Okubo Y, Trec S et al (2013) A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 31:1999–2007
30. Cristillo AD, Ferrari MG, Hudacik L et al (2011) Induction of mucosal and systemic antibody and T-cell responses following primeboost immunization with novel adjuvanted human immunodefi ciency virus-1-vaccine formulations. J Gen Virol 92:128–140
31. Gordon D, Kelley P, Heinzel S et al (2014) Immunogenicity and safety of Advax, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study. Vaccine 32(48):6469–6477
32. Gordon DL, Sajkov D, Woodman RJ et al (2012) Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic infl uenza vaccine containing Advax polysaccharide adjuvant. Vaccine 30:5407–5416
33. Honda-Okubo Y, Barnard D, Ong CH et al (2015) Severe acute respiratory syndromeassociated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol 89:2995–3007